Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation-Responsive Nanovesicles for Lung Cancer Chemoradiotherapy (Adv. Healthcare Mater. 28/2024)

IF 10 2区医学 Q1 ENGINEERING, BIOMEDICAL

Advanced Healthcare Materials Pub Date : 2024-11-11 DOI:10.1002/adhm.202470177

Fei Kang, Meng Niu, Zijian Zhou, Mingru Zhang, Hehe Xiong, Fantian Zeng, Jing Wang, Xiaoyuan Chen

引用次数: 0

Abstract

Nanovesicles

In article 2400908, Fei Kang, Jing Wang, Xiaoyuan Chen, and co-workers develop CV-Au NVs, defined as concurrent PARP inhibitor sensitization based on radiation-responsive nanovesicles. Upon irradiation, the nanovesicles are disintegrated, spatiotemporally releasing the loaded veliparib (PARP inhibitor) and cisplatin. The combined action of veliparib and cisplatin can increase radiation-induced DNA damage and promote apoptosis of tumor cells, enhancing the chemoradiotherapy efficacy of lung cancer.

Abstract Image

查看原文本刊更多论文

基于辐射响应性纳米微粒的时空并发 PARP 抑制剂增敏技术用于肺癌化放疗（Adv.）

纳米微粒在第 2400908 号文章中，Fei Kang、Jing Wang、Xiaoyuan Chen 及合作者开发了 CV-Au NVs，定义为基于辐射响应纳米微粒的 PARP 抑制剂同时增敏。辐照时，纳米颗粒崩解，在时空上释放出负载的veliparib（PARP抑制剂）和顺铂。veliparib和顺铂的联合作用可增加辐射诱导的DNA损伤，促进肿瘤细胞凋亡，从而提高肺癌的放化疗疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advanced Healthcare Materials 工程技术-生物材料

CiteScore

14.40

自引率

3.00%

发文量

600

审稿时长

1.8 months

期刊介绍： Advanced Healthcare Materials, a distinguished member of the esteemed Advanced portfolio, has been dedicated to disseminating cutting-edge research on materials, devices, and technologies for enhancing human well-being for over ten years. As a comprehensive journal, it encompasses a wide range of disciplines such as biomaterials, biointerfaces, nanomedicine and nanotechnology, tissue engineering, and regenerative medicine.